Skip to main content

Advertisement

Table 1 Baseline patient characteristics at the beginning of chemotherapy by treatment arm

From: Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy

Characteristics Platinum combination therapy (n = 24) Docetaxel monotherapy (n = 61) p value
Sex
Male 22 52 0.40a
Female 2 9  
Age, median (range), years 63.5 (46–74) 65 (42–77) 0.78b
Performance status
0 9 23 0.24a
1 15 34  
2 0 4  
Clinical stage at the time of recurrence
III 8 27 0.35a
IV 16 34  
Histology    
Adenocarcinoma 14 29 0.06a
Squamous cell carcinoma 8 28  
Large cell carcinoma 2 1  
Others 0 3  
EGFR mutation status    
Mutant 3 8 0.51a
Wild-type 8 13  
Unknown 13 40  
Smoking history
Current or former 20 45 0.44a
Never 3 9  
Unknown 1 7  
Number of treatment cycles, median (range) 2 (1–6) 2 (1–9) 0.50b
Response to prior chemoradiotherapy
Complete response 1 0 <0.05a
Partial response 10 47  
Stable disease 10 14  
Progressive disease 3 0  
Time since prior chemoradiotherapy
<6 months 10 19 0.36a
≥6 months 14 42  
Radiation dosage, median (range), Gy 60 (58–70) 60 (40–74) 0.52b
Prior chemotherapy regimen
CDDP + VNR 5 20 0.17a
CDDP + S1 7 16  
CBDCA + PTX 6 17  
Others 6 8  
Number of regimens after progression following second-line chemotherapy
0/1/2/≥3 11/10/3/0 12/22/12/15  
Median (range) 1 (0–2) 1 (0–6) <0.05b
  1. Abbreviations: EGFR, epidermal growth factor receptor; CDDP, cisplatin; VNR, vinorelbine; CBDCA, carboplatin; PTX, paclitaxel.
  2. aFisher’s exact test; b Wilcoxon rank-sum test.